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1. Introduction
Consuming a drug is equivalent to consume a risk. It is only when the benefit 
associated with the drugs are more than the risk, that the consumption of a drug 
is justified. Thus, it is benefit versus risk ratio of the drug which decides whether 
a drug is to be taken or not. The next question is how to measure risks and how to 
measure the benefits. Due to individualization of drugs to patients, it is the clinical 
judgment of the physician to identify what will benefit the patient. At the same 
time, risk associated with the drug can be ascertained by observations related to 
pharmacovigilance. The studies related to pharmacovigilance indicate what are the 
possible risks associated with the drug. Even drug can be associated with possible 
adverse reactions, intended or unintended. The only exception to this generality 
is the case of drug which is given in case of deficiency of specific components like 
vitamins or minerals. It is the study of possible adverse reactions of drugs which 
constitutes the essential content of Pharmacovigilance. This takes us to the defini-
tion of Pharmacovigilance.
Pharmacovigilance is the science and activities related to the detection, assess-
ment, understanding and prevention of adverse effects or any other possible drug-
related problems. [1] Spontaneous reporting of adverse events and adverse drug 
reactions is the commonest method utilized for generating safety data.
Major aims of pharmacovigilance are as follows:
• Early detection of hitherto unknown adverse reactions and interactions.
• Identification of risk factors and possible mechanisms underlying adverse 
reactions.
• Estimation of quantitative aspects of benefit/risk analysis and dissemination of 
information needed to improve drug prescribing and regulation.
Safety of patient is the most important when it comes about medicines. Various 
types of medicines are used since ancient ages and various rules and regulation 
were formed in modern era. If we look back in early twentieth century, the safety 
of patient was discussed first time when Biologics Control Act, 1902 was passed by 
USA [2, 3]. After that in 1962, USA promulgated a law stating that it is the manufac-
turer’s responsibility to prove safety and efficacy of the drug before getting market-
ing authorization. In 1963, a committee on Safety of drugs was established in UK. In 
1964, a system of “Yellow Cards” was established in UK to trace reporting safety 
of drugs by all users of drugs [4]. By 1964–1965, National Adverse Drugs Reaction 
reporting systems was initiated in countries like UK, Australia, New Zealand, 
Canada, West Germany and Sweden.
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Year Legislation/Act/Law/Event
1902 Biologics Control Act [2, 3]
Passed in 1902 by USA because many deaths were reported due to diphtheria vaccines tainted with tetanus.
1906 Pure Food and Drug Act [5]
Passed by US Congress, for preventing the manufacture, sale, or transportation of adulterated or misbranded or 
poisonous or deleterious foods, drugs, medicines, and liquors, and for regulating traffic therein, and for other purposes.
The bill was passed after significant public pressure which resulted from a novel by the journalist Upton Sinclair which 
exposed unhealthy practices of the meat industry in Chicago.
1937 Sulfanilamide Elixir [6]
used to treat streptococcal infections, which had been used without any issues in powder and tablet form.
A mass poisoning of 105 patients treated with an untested medication spurred Congress to empower the US Food and 
Drug Administration to monitor drug safety.
1938 Federal Food, Drug and Cosmetics Act [7]
As a result of sulfanilamide elixir incident, the Federal Food, Drugs and Cosmetics Act was passed, the statute that 
today remains the basis for FDA regulation.
1949 Council for International Organizations of medical sciences (CIOMS) [8]
Established jointly by WHO and UNESCO with the objective to facilitate and promote international activities in 
the field of biomedical sciences, especially when the participation of several international associations and national 
institutions is deemed necessary.
1961 Thalidomide tragedy [9, 10]
Thalidomide first entered the German market as an over-the-counter remedy in 1957.
A German newspaper soon reported 161 babies were adversely affected by thalidomide, leading the makers of the 
drug—who had ignored reports of the birth defects associated with the it—to finally stop distribution within Germany. 
Other countries followed suit and, by March of 1962, the drug was banned in most countries where it was previously 
sold.
1962 Kefauver-Harris [11]
This amendment was passed in the US Congress as a response to thalidomide tragedy. This law required evidence of 
drug efficacy and safety before marketing.
1964 Yellow Card Scheme [4]
Again in the wake of thalidomide tragedy the Yellow Card Scheme (UK) was established for collecting information on 
suspected adverse drug reaction (ADRs) of medicine to provide an early warning of possible hazards.
1967 WHO resolution
Resolution 20.51 laid basis for the international system of monitoring ADR.
1968 Medicines Act [12]
Established by UK to govern the control of medicines for human and veterinary, including manufacturing and supply.
1973 Pharmacovigilance System [13]
French Pharmacovigilance system implemented.
1982 Benoxaprofen [14]
Was removed from the market in the UK and USA after being linked to 3500 side effects and 61 deaths. Showing 
that despite progress and efforts to prevent disasters, these can still occur and great care is needed to ensure patient 
safety.
1990 CIOMS − 1 [15]
CIOMS−1: International reporting of Adverse Drug Reactions, released.
1991 European Rapid Alert System
Was signed into force to felicitate early exchange of information concerning possible safety hazards relating 
to marketing medicinal products. Reducing delay in acting on safety signals such as the case in Sulfanilamide elixir in 
1937
1995 European Medicines Agency
Established to harmonize the work of existing national medicine regulatory bodies.
2001 EU Clinical Trial directives [16]
Issued in April 2001 and approved and implemented in May 2004.Introduced more robust measures on the safe conduct 
of clinical trials. Volume 9A introduced to standardize post marketing PV systems in Europe.
2009 Black Triangle [17]
MHRA Black Triangle scheme to report all suspected adverse drug reaction to designated drugs.
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In 1962, International Center for monitoring of Adverse Drug Reaction by WHO 
was established in Geneva, which was later shifted to Uppsala in Sweden and this 
is the beginning of pharmacovigilance. From then, the WHO-supported Uppsala 
monitoring Centre has spearheaded many activities of pharmacovigilance all over 
the world (Table 1).
2. Current methods in pharmacovigilance
Pharmacovigilance is branch of pharmacoepidemiology but is restricted to the 
study, on an epidemiological scale, of drug events or adverse reactions.
Here ‘events’ means, recorded happenings during a period of drug monitoring 
in the patients notes, it may be due to the disease for which the drug is being given, 
some other intercurrent disease or infection, an adverse reaction to the drug being 
monitored or the activity of a drug being given concomitantly.
2.1 Hypothesis: generating methods
2.1.1 Spontaneous ADR reporting
Healthcare professionals are provided with forms upon which they can notify a 
authority of any suspected ADRs that they detect. The form is filled by healthcare 
professionals with direct interaction to patient after knowing the required informa-
tion directly from patients. Even the consumers can directly report with the help of 
form.
This system remains helpful to obtain the safety information of drug throughout 
the lifecycle of the drug or the length of stay of the drug in the market. Spontaneous 
reporting has led to the identification and verification of many unexpected and 
serious adverse drug reaction.
2.1.2 Prescription event monitoring
This method provides the ‘exposure data’ showing which patients have been 
exposed to the drug being monitored. Strength of this method is that it provides the 
number of reports and the number of patients exposed both being collected over a 
precisely known period of time or observations.
2.1.3 Other hypothesis: generating methods
In some cases, data being collected for general public health surveillance, such as 
cause of death files, cancer registries and birth defect registries are used to identify 
patterns of events that might be associated with medication use.
Year Legislation/Act/Law/Event
2012 Good Pharmacovigilance Practice (GvPs) [18]
Release of this replaced volume 9A. It expanded and clarifies the PV responsibility of marker authorization holders. 
Regularly updated and made available for public consultation.
2014 New Clinical Trial Regulation [19]
Signed into force to replace the 2001 EU-CTD. Standardized implementation across member states.
Table 1. 
Roadmap of current pharmacovigilance system.
Pharmacovigilance
4
2.2 Hypothesis: testing methods
2.2.1 Case-control studies
In this study, case is compared with controls susceptible to the disease but free 
of it. Here the exposure rate of case is compared with exposure rate in the controls. 
Special attention is needed in case definition so that the cases truly represent the spe-
cific outcome of interest (e.g. Stevens-Johnson syndrome and not all cases of rash).
2.2.2 Crossover design
Very useful design for the evaluation of events with onset shortly after treatment 
initiated. Here cases are identified not controls. A drug association is evaluated 
through comparing frequency of exposure at the time of the event with frequency 
of exposure at a different time for the same individuals. This design is less subject to 
bias than case–control studies because individuals serve as their own controls.
3. Causality assessment in pharmacovigilance
While reporting any adverse reaction, it is necessary to establish causal relation 
between the suspected drug and the observed effect. It is also possible that one of the 
diseases processes, interaction of the drug on disease process or even lack of effect of 
a drug exacerbating the disease process may be involved in the observed effect.
Causality 
term
Assessment criteria
Certain Event or laboratory test abnormality, with plausible time relationship to drug intake
• Cannot be explained by disease or other drugs
• Response to withdrawal plausible (pharmacologically, pathologically)
• Event definitive pharmacologically or phenomenologically (i.e. an objective and 
specific medical disorder or a recognized pharmacological phenomenon)
• Rechallenge satisfactory, if necessary
Probably/
likely
• Event or laboratory test abnormality, with reasonable time relationship to drug intake
• Unlikely to be attributed to disease or other drugs
• Response to withdrawal clinically reasonable
• Rechallenge not required
Possible Event or laboratory test abnormality, with reasonable time relationship to drug intake
• Could also be explained by disease or other drugs
• Information on drug withdrawal may be lacking or unclear
unlikely • Event or laboratory test abnormality, with a time to drug intake that makes a relation-
ship improbable (but not impossible)
• Disease or other drugs provide plausible explanations
Conditional/
unclassified
• Event or laboratory test abnormality
• More data for proper assessment needed, or
• Additional data under examination
Unassessable/
unclassifiable
• Report suggesting an adverse reaction
• Cannot be judged because information is insufficient or contradictory
• Data cannot be supplemented or verified
Table 2. 
WHO-UMC system proposed by World Health Organization.
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The causality assessment system proposed by the World Health Organization 
Collaborating Centre for International Drug Monitoring, the Uppsala Monitoring 
Centre (WHO–UMC) [20], and the Naranjo Probability Scale [21] are the generally 
accepted and most widely used methods for causality assessment in clinical practice 
as they offer a simple methodology (Tables 2 and 3).
4. Signal detection
As per World Health Organization, signal of adverse drug reaction is: “reported 
information on a possible causal relationship between an adverse event and a drug, 
the relationship being unknown or incompletely documented previously” [22].
A signal is therefore very tentative in nature; the first expression that something 
might be wrong with a medicinal product, or a hint given by new information 
which might support or explain a medicinal product–adverse reaction relationship 
already known [23].
Usually, more than a single report is required for signal detection (SD), depend-
ing on the seriousness of the event and the quality of the information. Once a signal 
is detected, one can then analyze and confirm it. In detecting signals from large 
ADR databases, however, one has to use a procedure that is sensitive (low false 
negativity) and specific (high true positivity) for the purpose [24, 25].
Different methods are being developed till today for the detection of signal. 
In that statistical method is very useful and very under estimated method. Such 
method is data mining approach, in which important and useful information are 
automatically and continuously extracted from large amounts of data, it is a form of 
exploratory data analysis and a key component of the knowledge discovery process. 
This approach seems particularly valuable and can be used on any large data set.
Data mining approach is divided into mainly two parts: frequentist and Bayesian 
methods.
Questions Yes No Do not 
know
Are there previous conclusion reports on this reaction? +1 0 0
Did the adverse event appear after the suspect drug was 
administered?
+2 −1 0
Did the AR improve when the drug was discontinued or a 
specific antagonist was administered?
+1 0 0
Did the AR reappear when drug was re-administered? +2 −1 0
Are there alternate causes [other than the drug] that could 
solely have caused the reaction?
−1 +2 0
Did the reaction reappear when a placebo was given? −1 +1 0
Was the drug detected in the blood [or other fluids] in a 
concentration known to be toxic?
+1 0 0
Was the reaction more severe when the dose was increased or 
less severe when the dose was decreased?
+1 0 0
Did the patient have a similar reaction to the same or similar 
drugs in any previous exposure?
+1 0 0
Was the adverse event confirmed by objective evidence? + 0 0
Scoring for Naranjo algorithm: >9 = definite ADR; 5–8 = probable ADR; 1–4 = possible ADR; 0 = doubtful ADR.
Table 3. 
Naranjo ADR probability scale—items and score.
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4.1 Frequentist method
They are particularly appealing and therefore widely used due to the fact that 
they are relatively easy to understand, interpret and compute as they are based on 
the same principles of calculation using the 2 × 2 table.
Proportional reporting ratio (PRR), Reporting odd ratio (ROR), chi-square 
ratio, 95% confidence interval of PRR and observed to expected ratio are calculated.
4.2 Bayesian method
Bayesian methods interpret the concept of probability as the degree to which a 
person believes a proposition. Bayesian inference starts with a pre-existing subjec-
tive personal assessment of the unknown parameter and the probability distribu-
tion (called prior distribution).
The signal metric or signal score in BCPNN is the information component (IC) 
(Table 4).
5. Pharmacovigilance and ICH regulations
So far, pharmacovigilance-related topics entered the ICH process in two waves. 
The first wave resulted in adoption of the ICH Topic ICH-E2A in 1994 with an 
extension to this work in the form of E2B and E2C, finalized between 1996 and 
1997. The second wave started in 2002 with three further ICH topics, E2D, E2C 
Addendum and E2E, finalized between 2003 and 2004 (Figure 1).
5.1 Key points addressed in the ICH-E2A
• Definitions for AE and ADR in the pre-authorization phase [26]
• Criteria for serious AE/ADR
Method Advantage Limitations Regulatory Agencies 
using the method
Frequentist methods
Proportional 
reporting ratio 
(PRR)
Easily applicable and 
interpretable, more 
sensitive compared to 
Bayesian method
Cannot be calculated 
for all drug-event 
combinations, low 
specificity
EMA (EudraVigilance),
Italian Regulatory 
Agency
Reporting odd ratio 
(ROR)
Easily applicable and 
interpretable, more 
sensitive compared to 
Bayesian method
Odd ration cannot be 
calculated if denominator 
is zero
Lareb (Netherlands)
Bayesian methods
Multi-item Gamma 
Poisson Shrinker
Always applicable, 
more specific 
as compared to 
frequentist methods
Relatively non transparent 
for people non familiar 
with Bayesian statistics, 
lower sensitivity
FDA (AERS)
Bayesian 
Confidence 
Propagation Neural 
Network (BCPNN)
Always applicable, 
more specific 
as compared to 
frequentist methods
Relatively non transparent 
for people non familiar 
with Bayesian statistics, 
lower sensitivity
UMC (WHO-VigiBase)
Table 4. 
Data mining methods.
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• Expectedness of an AE/ADR based on clinical observation and its documenta-
tion in the applicable product information
• Causality assessment as good case practice for AE/ADR cases from clinical trials
• Implied possible causality for spontaneously reported ADR cases
• Standards for expedited reporting from clinical trials
• Definition of minimum case report information for report submission to 
authorities
• Follow-up reporting
• Unblinding procedures for serious ADRs
• Reporting of emerging information on post-study ADRs
• Reporting requirement for active comparator
5.2 Key points addressed in the ICH-E2D
• Definitions for AE and ADR in the post-authorization phase [27]
• Criteria for serious AE/ADR in accordance with ICH-E2A
• Expectedness of an AE/ADR based on clinical observation and its documen-
tation in the authorized product information; explanations regarding class 
effects
• Differentiation between sources of unsolicited and solicited reports
• Explanation on stimulated (but unsolicited) reporting
• Standards for expedited reporting in post-authorization phase
Figure 1. 
Pharmacovigilance and ICH.
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• Definition of minimum case report information for report submission to 
authorities with explanations
• Follow-up reporting
• Lack of efficacy reporting needs
• Guidance on ADR narratives
• Guidance on ADR case assessment
• Management of cases of exposure during pregnancy
• Explanation on reporting responsibility of marketing authorization holder 
despite any contractual relationship in place
5.3 Key points addressed in the ICH-E2B(M)
• Description of all data elements of ADR case reports: title and content of each 
data field [28]
• Technical specifications such as field length and field value for each of the data 
fields and the related additional technical data fields
• List of abbreviations for units
• List of units for time intervals
• List of routes of administration
5.4 Key points addressed in the ICH-E2C
• Inclusion of all product presentations in one PSUR [29]
• Concept of international birthdates of a product, determining the data lock 
points of PSURs
• Provision to submit a set of PSURs, each covering subsequent 6 months, to 
facilitate PSUR submission according to local frequency
• Description of all data sources to be covered in a PSUR
• Inclusion of worldwide information on marketing authorization status and 
regulatory safety-related action, ADR and exposure data
• Use of company core safety information (CCSI) as reference and concept of 
unlistedness of an ADR (i.e. unlisted in comparison to the CCSI versus unex-
pected in comparison with locally authorized product information)
• Presentation of individual case history
• Formats of ADR line listings and summary tabulations
• Presentation of exposure data
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5.5 Key points addressed in the ICH-E2E
• Elements for the safety specification as summary of identified risks, risks 
potentially arising from populations and situations that have not yet been 
adequately studied and potential other risks [30]
• Format of a pharmacovigilance plan based on the safety specification
• Within the pharmacovigilance plan, the description of routine pharmaco-
vigilance as minimum and inclusion of a safety action plan for specific issues/
missing information as needed
• Format of safety action plan, with the description of rationale for action and 
timetable for evaluation and reporting (‘milestones’)
• Possible synchronization of timetable with regulatory timetable for post-
authorization assessment, such as PSUR assessment or marketing authoriza-
tion renewal assessment
• Principles for design and conduct pharmacoepidemiological studies of non-
experimental design with references to international guidelines
• Overview of methods for data collection to investigate the known or unknown 
risks and references
6. Pharmacovigilance in pediatric population
Pediatric population is defined as age between 0 and 18 years of age. Since many 
ages, pediatrician deals with limited available medicines specifically made for 
children. The reason behind limited availability of medicines is lack of clinical trials 
in this age group. Pediatricians are left with no choice other than prescribing it as 
“off-label” basis as these medicines have not been adequately tested and or formu-
lated and authorized for use in appropriate pediatric age group. So these health care 
providers should be aware of risk involved in prescribing and administering such 
drugs to children [1].
Risk of adverse reactions increases with “off-label” use of drugs and so regula-
tory authorities play an important role in reminding health care providers to report 
adverse drug reactions and process of pediatric pharmacovigilance [31]. Specific 
problems associated with pediatric population are lack of clinical trials, under or 
over dosage, lack of pharmacokinetics and dose-finding studies; drug induced 
growth and developmental disorders as well as delayed ADRs [31].
Various stakeholders that play a role in pharmacovigilance are health profession-
als, parents, pharmaceutical industry, patient organizations, national healthcare 
systems, etc.
Different regulatory guidance’s available for pediatric pharmacovigilance are but 
not limited to:
ICHE2E
EMEA: Guideline on conduct of pharmacovigilance for medicines used by the 
pediatric population.
EMEA: Guideline on conduct of pharmacovigilance for vaccines.
Points to be considered for future in pediatric pharmacovigilance are [32]:
Pharmacovigilance
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• Pediatric population should be taken into account during all phases of pharma-
covigilance cycle
• Encourage ADR reporting
• Expanding definition of ADR to include off-label, misuse, error.
• Risk management plans
• Signal detecting systems
• Additional monitoring system
7. The future
The drugs can viewed, in general terms, like any other commodity. Patients will 
be able to choose what is best for them on the basis of information they are given. 
Drugs with relatively less benefit or more risk will find an appropriate market level. 
We believe this involves the public understanding more about benefit and risk, 
more suitable information coming from regulators and industry regarding benefit 
and risk of drugs, health professionals being able to interpret information for singu-
lar situations and the law and media playing a more constructive role in the whole 
process. The situation is undoubtedly more complicated than this, and the issues 
of communications in a crisis involving safety issues with a drug not only affect the 
situation but have a more general impact. These high profiles issues deserve special 
attention as does the impact of new communications media and sources.
Pharmacovigilance benefits everybody. The patients are protected from unsafe 
drugs, doctors and pharmaceutical industry keep their reputations intact and drug 
regulators receive pertinent data that helps them to take regulatory decisions.
It is expected that with the involvement of all related stakeholders, 
Pharmacovigilance program will help in reducing the cost of damages caused by 
drugs to minimal level. It will also try to prevent drug-related damages if appropri-
ate care is taken by physicians on the basis of feedback from the pharmacovigilance 
program.
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